CN103585215A - Medicine for treating heart failure and preparation method thereof - Google Patents
Medicine for treating heart failure and preparation method thereof Download PDFInfo
- Publication number
- CN103585215A CN103585215A CN201310609028.0A CN201310609028A CN103585215A CN 103585215 A CN103585215 A CN 103585215A CN 201310609028 A CN201310609028 A CN 201310609028A CN 103585215 A CN103585215 A CN 103585215A
- Authority
- CN
- China
- Prior art keywords
- medicine
- heart failure
- group
- treatment
- radix ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of traditional Chinese medicine, in particular to a medicine for treating heart failure and a preparation method thereof. The medicine preparation method comprises the following steps: respectively pulverizing Radix Ginseng cruda and Gekko to obtain Radix Ginseng cruda powder and Gekko powder; mixing the Radix Ginseng cruda powder and the Gekko powder to obtain a mixture; preparing the traditional Chinese preparation from the mixture to obtain the medicine for treating heart failure. The medicine provided by the invention is composed of the Radix Ginseng cruda and the Gekko in a range restricted by the embodiment I, and can be used for treating acute and chronic heart failure caused by various reasons without adverse reactions of patients or toxic and side effects as a traditional Chinese medicine. Additionally, what should be noted is that diseases treated by the medicines are completely different if the medicines have large difference in composition of the Radix Ginseng cruda powder and the Gekko.
Description
Technical field
The present invention relates to the field of Chinese medicines, in particular to treating medicine of heart failure and preparation method thereof.
Background technology
Heart failure (heart failure, HF) is the end stage eventually of various heart diseases, and its treatment is thorny, prognosis is not good, and patient only has 5 annual survival rates, similar with malignant tumor.According to statistics, nearly 5,000,000 heart failure patients of the U.S., and have every year 500000 new cases.More domestic researchs show, because heart failure accounts for 16.3%～17.9% of the cardiovascular patient sum of being in hospital in hospital, within 60 years old, above person surpasses 60%, and the cardiac function while being admitted to hospital is all with III level (42.5%～43.7%) in the majority, and mostly is the acute exacerbation of chronic heart failure.Heart failure increased and has the trend raising gradually with the age, the right side of fifty, sickness rate is about 1%, and more than 80 years old, sickness rate is about 10%, in the sufferer of being in hospital, approximately 80% over 65 years old, along with aged tendency of population, heart failure is just becoming the great hygienic issues that affects human life's health, and therefore, developing effective medicine is current important research direction.
In correlation technique, the conventional medicine for the treatment of heart failure has: angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor antagonist (ARB), beta-2 adrenoceptor antagonist (β-blockers), digitalis preparation etc., although these medicines have certain therapeutical effect, but be Western medicine, after long-term taking, all can cause untoward reaction, as ACEI, ARB easily cause hypotension, β-blockers, digitalis preparation cause that heart rate is slack-off.
Summary of the invention
The object of the present invention is to provide medicine for the treatment of heart failure and preparation method thereof, to solve the above problems.
The medicine that treatment heart failure is provided in an embodiment of the present invention, consists of the following composition: by weight, and Radix Ginseng 2.8-3.2 part, Gecko 0.9-1.1 part.
The preparation method that the medicine of above-mentioned treatment heart failure is provided in an embodiment of the present invention, comprises the following steps:
Respectively Radix Ginseng and Gecko are ground into powder, obtain Radix Ginseng powder and Tokay Gecko;
Radix Ginseng powder and Tokay Gecko are mixed, obtain mixture;
Mixture is made to Chinese medicine preparation, the medicine of the heart failure that obtains medical treatment.
Medicine of the treatment heart failure of the above embodiment of the present invention and preparation method thereof, by Radix Ginseng and Gecko, according to embodiment mono-limited range, form, can treat the acute and chronic heart failure due to a variety of causes, and can not cause patient's untoward reaction, as Chinese medicine without any toxic and side effects, its curative mechanism is to set about from the pathology of heart failure: according to the clinical manifestation of heart failure patient, this disease can be belonged to the categories such as " the syndrome of dyspnea ", " cardiopalmus ", " thoracic obstruction ".According to clinical observation for many years, find heart failure patient deficiency of heart-QI, heart-yang virtual loss, yang deficiency can not be harnessed the river, therefore there is fluid-retention stagnating in the interior, even spread unchecked, and cause the icepro heart, penetrates lung, sends out as critical illnesses such as collapse syndrome caused by dyspnea.Therefore, adjust reinforcing the heart gas, warmly invigorating heart-YANG when running through treatment heart failure all the time.According to " treating different diseases with the same therapeutic principle ", " cardiopulmonary are ruled together " scheduling theory, can be by medicine of the present invention for the treatment of heart failure, and in diagnosis and treatment process, find to truly have significant curative effect, Radix Ginseng strongly invigorating primordial QI wherein, can mend the gas of the whole body; The salty temperature of Gecko, as kidney channel, can warming and recuperating the kidney-YANG, kidney yang is human body positive the dominator of QI all over the body, and kidney-replenishing can reinforcing the heart sun, and both are harmonious, reinforce functional activities of the heart, warming and recuperating the kidney-YANG, conforms to for the heart failure patient medicine card of motive virtual loss, declination of heart-YANG.
In addition, it should be noted in the discussion above that when Radix Ginseng and Gecko proportion of composing difference are larger, form the complete difference of disease category meeting that medicine is treated.
Accompanying drawing explanation
Fig. 1 shows the effect comparison diagram of medicine of the present invention to pressure overload induced heart failure rats LVEF;
Fig. 2 shows the effect comparison diagram of medicine of the present invention to pressure overload induced heart failure rats left ventricular mass index;
Fig. 3 shows the microscope figure of sham operated rats to the effect of pressure overload myocardium of rats with heart failure plumpness;
Fig. 4 shows the microscope figure of model group to the effect of pressure overload myocardium of rats with heart failure plumpness;
Fig. 5 shows the microscope figure of fasudil group to the effect of pressure overload myocardium of rats with heart failure plumpness;
Fig. 6 shows the microscope figure of medicine group of the present invention to the effect of pressure overload myocardium of rats with heart failure plumpness;
Fig. 7 shows the action diagram that medicine of the present invention is expressed pressure overload myocardium of rats with heart failure RhoA;
Fig. 8 shows the effect comparison diagram that medicine of the present invention is expressed pressure overload myocardium of rats with heart failure ROCK1;
Fig. 9 shows the effect comparison diagram of medicine of the present invention to pressure overload myocardium of rats with heart failure NOX2, NOX4.
The specific embodiment
Below by specific embodiment, also by reference to the accompanying drawings the present invention is described in further detail.
Embodiment mono-
The medicine for the treatment of heart failure, consists of the following composition: by weight, and Radix Ginseng 2.8-3.2 part, Gecko 0.9-1.1 part.
At the medicine of above-mentioned treatment heart failure, Radix Ginseng and Gecko can adopt any part within the scope of its umber, and for example embodiment bis-to six.
The formula of embodiment bis-to six is as shown in table 1.
The formula of table 1 embodiment bis-to six
Above the medicine of all embodiment forms according to embodiment mono-limited range by Radix Ginseng and Gecko, can treat the acute and chronic heart failure due to a variety of causes, and can not cause patient's untoward reaction, as Chinese medicine without any toxic and side effects, its curative mechanism is to set about from the pathology of heart failure: according to the clinical manifestation of heart failure patient, this disease can be belonged to the categories such as " the syndrome of dyspnea ", " cardiopalmus ", " thoracic obstruction ".According to clinical observation for many years, find heart failure patient deficiency of heart-QI, heart-yang virtual loss, yang deficiency can not be harnessed the river, therefore there is fluid-retention stagnating in the interior, even spread unchecked, and cause the icepro heart, penetrates lung, sends out as critical illnesses such as collapse syndrome caused by dyspnea.Therefore, adjust reinforcing the heart gas, warmly invigorating heart-YANG when running through treatment heart failure all the time.According to " treating different diseases with the same therapeutic principle ", " cardiopulmonary are ruled together " scheduling theory, can be by medicine of the present invention for the treatment of heart failure, and in diagnosis and treatment process, find to truly have significant curative effect, Radix Ginseng strongly invigorating primordial QI wherein, can mend the gas of the whole body; The salty temperature of Gecko, as kidney channel, can warming and recuperating the kidney-YANG, kidney yang is human body positive the dominator of QI all over the body, and kidney-replenishing can reinforcing the heart sun, and both are harmonious, reinforce functional activities of the heart, warming and recuperating the kidney-YANG, conforms to for the heart failure patient medicine card of motive virtual loss, declination of heart-YANG.
In addition, it should be noted in the discussion above that when Radix Ginseng and Gecko proportion of composing difference are larger, form the complete difference of disease category meeting that medicine is treated.
Embodiment seven
Above the medicine of all embodiment all can adopt following preparation method, comprises the following steps:
Respectively Radix Ginseng and Gecko are ground into powder, obtain Radix Ginseng powder and Tokay Gecko;
Radix Ginseng powder and Tokay Gecko are mixed, obtain mixture;
Mixture is made to Chinese medicine preparation, the medicine of the heart failure that obtains medical treatment.
Wherein, Chinese medicine preparation can be granule, powder or capsule.The method of mixing can adopt multiple, and for example concussion mixes.When the particle diameter of Radix Ginseng powder adopts 2mm, easier preparation is shaped, and assimilation effect is better.The particle diameter of same Tokay Gecko also preferably adopts 2mm.
Embodiment eight
Above the medicine of all embodiment all also can adopt following preparation method, comprises the following steps:
1, the pulverizer that Radix Ginseng is put into after clean is pulverized approximately 10 minutes repeatedly, is ground into corase meal completely to decoction pieces.
2, step 1 gained Radix Ginseng corase meal is placed in to No. 10 medicines sieves after cleaning, vibration medicine sieve, fine powder under collection screen, after unsifted Radix Ginseng powder is again put back in pulverizer and again to be pulverized, after No. 10 medicine sieves, fine powder under collection screen, repeats this step, until collect enough Radix Ginseng fine powders.
3, Gecko is dispelled cephalopodium, after remaining part is shredded by sterile scissors, puts into clean pulverizer and repeatedly pulverizes approximately 10 minutes, obtains Gecko corase meal.
4, step 3 gained Gecko corase meal is inserted No. 10 to medicine sieve, with the stone roller pestle of sterilizing, Tokay Gecko is rolled and sieved, Gecko smalls under collection screen, unsifted Gecko corase meal is reentered into pulverizer fully to be pulverized, after No. 10 medicine sieves, repeat this step, to collecting enough Gecko smalls.
5, take step 2 gained fine powder and step 3 gained smalls, mass ratio is on request put into clean large beaker by both, powder cumulative volume is no more than 1/3 of beaker, with after the good beaker of plastic sheeting capping, after fully concussion mixes approximately 20 minutes, obtains medicine of the present invention.
In order further to explain the technique effect of medicine of the present invention, below provide concrete test example.
Below the loose group of Fig. 1 of indication and the ginseng clam in Fig. 2 all refers to medicine group of the present invention.
Test example 1:
The improvement effect of medicine of the present invention to pressure overload induced heart failure rats cardiac ultrasonic.
The present invention studies pressure overload induced heart failure rats cardiac ultrasonic.With attenuates pressure-overload left method, set up Chronic Pressure load DHF model, respectively modeling administration 5 weeks and modeling 8 weeks administration 16 weeks afterwards after 3 days, all find that medicine of the present invention has the good effect that improves induced heart failure rats cardiac ultrasonic, modeling is administration and sham operated rats comparison after 3 days, the obviously decline (P < 0.05) of model group cardiac ejection fraction (EF) value; With model group comparison, Captopril group EF value rises obviously (P < 0.05), and medicine group of the present invention and model group comparison, there is ascendant trend (experimental data is in Table 2) in EF value.After modeling 8 weeks, with sham operated rats comparison, the EF value of each group all declines (P<0.01) to some extent, interventricular septal thickness (IVSD) increases (P<0.05), with model group comparison, each treatment group EF value all obviously raises (P<0.01), fasudil group and medicine group no difference of science of statistics of the present invention (P > 0.05); With model group comparison, interventricular septum thickness at enddiastole (IVSD) no significant difference of each group.Left ventricular posterior wall thickness (LVPWd) aspect, with sham operated rats comparison, model group obviously raise (P<0.01), fasudil group also increases (P<0.05), with model group comparison, medicine group of the present invention decreases, and (P<0.05) (experimental data is in Table 3, Fig. 1).
Table 2 medicine of the present invention, captopril on the impact of cardiac ejection fraction (LVEF) and comparison (
n=8)
Table 3 medicine of the present invention, fasudil on the impact of EF, IVSD, LVPWd and comparison (
n=9)
Test example 2: the effect of medicine of the present invention to pressure overload induced heart failure rats left ventricular mass index.
The present invention studies pressure overload induced heart failure rats heart left ventricle performance figure.With attenuates pressure-overload left method, set up Chronic Pressure load DHF model equally, modeling is administration discovery in 5 weeks and sham operated rats comparison after 3 days, model group left ventricular mass and weight ratio (LVW/BW, left ventricular mass index) be rising (P < 0.01) obviously; With model group comparison, all there is obvious decline in each treatment group LVW/BW, wherein with Captopril group decline more remarkable (experimental data is in Table 4), modeling is administration discovery in 16 weeks and sham operated rats comparison after 8 weeks, each organizes all risings (P<0.01) to some extent of LVMI, with model group comparison, each treatment group LVMI is decline (P<0.01) to some extent all, and medicine group of the present invention is better than fasudil group (P<0.01), and (experimental data is in Table 5, Fig. 2).
Table 4 medicine of the present invention, captopril on the impact of left heart performance figure and comparison (
n=8)
| Group | N | Left cardiac index (mg/g) |
| Sham operated rats | 8 | 1.43±0.12 |
| Model group | 8 | 2.16±0.14 |
| Fasudil group | 8 | 1.40±0.25 |
| Medicine group of the present invention | 8 | 1.88±0.87 |
Table 5 medicine of the present invention, fasudil on the impact of left heart performance figure and comparison (
n=9)
Test example 3: the effect of medicine of the present invention to pressure overload induced heart failure rats hemodynamic index
The present invention studies pressure overload induced heart failure rats heart left ventricle performance figure.With attenuates pressure-overload left method, set up Chronic Pressure load DHF model equally, modeling rear administration in 8 weeks 16 weeks, with fasudil medicine in contrast, find respectively to organize left chamber EDP (LVEDP), heart rate (HR) no significant difference (P > 0.05).With sham operated rats comparison, the speed (+dp/dt) that its excess-three group left ventricular systolic pressure (LVSP) and isovolumic contraction period left ventricular pressure power rise declines (P < 0.01) to some extent ,-dp/dt rises (P < 0.01).With model group comparison, medicine group LVSP of the present invention ,+dp/dt (the P < 0.01 that obviously rises, P < 0.05), the speed (dp/dt) that isovolumic contraction period left ventricular pressure power declines obviously reduces (P < 0.01).With the comparison of fasudil group, medicine group LVSP of the present invention declines (P < 0.01) to some extent, and-dp/dt rises (P < 0.01) to some extent ,+dp/dt no difference of science of statistics (P > 0.05).(experimental data is in Table 6,7).And with captopril medicine in contrast, find that, aspect the index LVSP and dp/dtmax of reaction ventricular systolic function, sham operated rats LVSP, apparently higher than model group (P<0.05), has no notable difference between its excess-three group; Model group dp/dtmax obviously reduces (P<0.01) compared with other three groups.On the index LVEDP of reaction diastolic function and-dp/dtmax, with sham operated rats comparison, medicine group of the present invention, model group and Captopril group LVEDP obviously raise, and do not find notable difference for these three groups; The maximum rate (dp/dtmax) that sham operated rats isovolumic contraction period left ventricular pressure power declines is starkly lower than other each groups, between model group, medicine group of the present invention and Captopril group, have no notable difference explanation, except model group, it is not yet obviously impaired that each organizes rat cardiac ventricular contractile function, and the diastolic function of each group is impaired in various degree, Captopril group, medicine group of the present invention and model group have all reached the standard (experimental data is in Table 8) of diastolic heart failure.
Table 6 medicine of the present invention, fasudil on the impact of HR, LVSP, LVEDP and comparison (
)
Table 7 medicine of the present invention, fasudil on the impact of dp/dt ,-dp/dt and comparison (
)
Table 8 medicine of the present invention, captopril to the effect of each group hemodynamics index (
)
Test example 4: medicine of the present invention is plump to pressure overload myocardium of rats with heart failure, the effect of myocardial cell cross-sectional area (CSA).
The present invention studies pressure overload induced heart failure rats heart left ventricle performance figure.With attenuates pressure-overload left method, set up Chronic Pressure load DHF model equally, modeling is administration discovery in 16 weeks and sham operated rats comparison after 8 weeks, and model group myocardial cell cross-sectional area (CSA) obviously increases (P<0.01); Captopril group and medicine group CSA of the present invention are all lower than model group, but no difference of science of statistics (experimental data is in Table 9) is compared in this improvement effect of two groups with model group.Take fasudil as contrast medicine, and om observation is found, sham operated rats myocardial cell clear in structure, and cardiac muscle fiber marshalling, form size is basically identical, and myocardium transverse diameter is moderate; Model group myocardial cell transverse diameter increases, arrangement disorder, and visible obviously interstitial proliferation, nucleus dyeing in the part visual field is unintelligible; Fasudil group and medicine group of the present invention are better than model group, and the situations such as hypertrophy, interstitial proliferation alleviate, and medicine group of the present invention is better than fasudil group (sham operated rats, model group, fasudil group and drug component of the present invention are not shown in Fig. 3-6).
Table 9 respectively organize rat HE dyeing observe myocardial cell cross-sectional area (μ m2) (
)
| Grouping | n | CSA |
| Sham operated rats | 8 | 323.71±94.40 |
| Model group | 8 | 515.28±131.80 |
| Captopril group | 8 | 497.84±148.95 |
| Medicine group of the present invention | 8 | 507.95±35.20 |
Test example 5: the effect that medicine of the present invention is expressed pressure overload myocardium of rats with heart failure RhoA, ROCK1
The present invention studies pressure overload induced heart failure rats heart left ventricle performance figure.With attenuates pressure-overload left method, set up Chronic Pressure load DHF model equally, modeling is administration discovery in 16 weeks and sham operated rats comparison after 8 weeks, RhoA, ROCK1 expressions of all the other each group obviously raise (P<0.01), compare with model group, fasudil group, medicine group expression of the present invention decline to some extent (P<0.01), and fasudil group is less than medicine group of the present invention (P<0.01) (in Table 10, Fig. 7,8).
The mrna expression of Biao10Ge Zu rat left chamber cardiac muscle RhoA, ROCK1 (
)
Test example 6: the effect that medicine of the present invention is expressed pressure overload myocardium of rats with heart failure NOX2, NOX4.
The present invention studies pressure overload induced heart failure rats heart left ventricle performance figure.With attenuates pressure-overload left method, set up Chronic Pressure load DHF model equally, NADPH (NADPH) the Oxidase Expression amount comparison of modeling rear administration in 8 weeks discovery in 16 weeks and sham operated rats, model group is expressed and is increased (P<0.01); With model group comparison, medicine group of the present invention and fasudil group expression reduce (P<0.01), and medicine group of the present invention has lower trend (P<0.01) (in Table 11, Fig. 9) compared with fasudil group.
Table 11 medicine of the present invention, fasudil on the impact of NOX2, NOX4 and comparison (
)
Test example 7: the effect of medicine of the present invention to heart failure patient cardiac function, traditional Chinese medical science disease integration, blood plasma BNP
The present invention studies the cardiac function of Drug therapy heart failure patient of the present invention, traditional Chinese medical science disease integration, blood plasma BNP.60 routine patients with congestive heart failure are divided into two groups at random, and matched group (30 example) gives the conventional heart failure resistance treatment of doctor trained in Western medicine, and treatment group (30 example) adds medicine of the present invention on doctor trained in Western medicine conventional therapy basis, and be 8 weeks two groups of courses for the treatment of; Before and after observing treatment, tcm syndrome integration changes, and with B ultrasonic, detects Left Ventricular Ejection Fraction (LVEF), the often amount of fighting (SV), cardiac output (CO), E/A value, mensuration serum heart failure quantitative marker (BNP) level, and evaluate clinical efficacy.The cardiac function curative effect total effective rate that found that treatment group, matched group is respectively 86.67%, 46.67%, and between group, Different therapeutical effect has statistical significance (P<0.01).After two groups of treatments, tcm syndrome integration, BNP level are all treated the front (P<0.05 of decline, P<0.01), syndrome integration, BNP level are all lower than matched group (P<0.01) and after treatment group treatment.After treatment, two groups of LVEF, SV, CO all improve (P<0.05), and after treatment group treatment, LVEF, SV, CO, the improvement of E/A value are better than matched group (P<0.05, P<0.01).(in Table 12,13,14).
Tcm syndrome integral contrast before and after table 12 liang group treatment (
)
| Group | N | Before treatment | After treatment |
| Matched group | 30 | 22.73±5.35 | 18.50±7.0 |
| Treatment group | 30 | 22.20±5.09 | 9.77±4.05 |
Table 13 liang group treatment Plasma Before And After BNP comparison (
)
| Group | N | Before treatment | After treatment |
| Matched group | 30 | 707.63±259.18 | 557.33±204.43 |
| Treatment group | 30 | 711.07±270.56 | 338.33±70.03 |
Echocardiography result comparison before and after table 14 liang group treatment (
)
The animal experiment study of above 7 test examples shows: medicine of the present invention can effectively improve pressure overload induced heart failure rats cardiac ultrasonic Left Ventricular Ejection Fraction (LVEF), hemodynamic index, left ventricular mass index (LVMI), and can suppress Heart Failure Wistar Rats myocardial hypertrophy, cardiomyocyte apoptosis and myocardium interstitial fibrosis.In to the regulating action of Rho/ROCK path, medicine of the present invention can suppress the expression of RhoA, ROCK1, has this path effect of certain inhibition, clinical research shows, medicine of the present invention can obviously improve heart failure patient traditional Chinese medical science disease integration, reduces blood plasma BNP, improves Cardiac Function of Patients.
The foregoing is only the preferred embodiments of the present invention, be not limited to the present invention, for a person skilled in the art, the present invention can have various modifications and variations.Within the spirit and principles in the present invention all, any modification of doing, be equal to replacement, improvement etc., within all should being included in protection scope of the present invention.
Claims (10)
1. the medicine for the treatment of heart failure, is characterized in that, consists of the following composition:
By weight, Radix Ginseng 2.8-3.2 part, Gecko 0.9-1.1 part.
2. the medicine for the treatment of heart failure according to claim 1, is characterized in that, consists of the following composition:
By weight, 2.8 parts of Radix Ginseng, 1.1 parts of Geckos.
3. the medicine for the treatment of heart failure according to claim 1, is characterized in that, consists of the following composition:
By weight, 3.2 parts of Radix Ginseng, 0.9 part of Gecko.
4. the medicine for the treatment of heart failure according to claim 1, is characterized in that, consists of the following composition:
By weight, 3 parts of Radix Ginseng, 1 part of Gecko.
5. the preparation method of the medicine of the treatment heart failure described in claim 1-4 any one, is characterized in that, comprises the following steps:
Respectively Radix Ginseng and Gecko are ground into powder, obtain Radix Ginseng powder and Tokay Gecko;
Described Radix Ginseng powder and described Tokay Gecko are mixed, obtain mixture;
Described mixture is made to Chinese medicine preparation, the medicine of the heart failure that obtains medical treatment.
6. the preparation method of the medicine for the treatment of heart failure according to claim 5, is characterized in that, described Chinese medicine preparation is powder.
7. the preparation method of the medicine for the treatment of heart failure according to claim 5, is characterized in that, described Chinese medicine preparation is capsule.
8. the preparation method of the medicine for the treatment of heart failure according to claim 5, is characterized in that, the method for described mixing is: concussion mixes.
9. the preparation method of the medicine for the treatment of heart failure according to claim 5, is characterized in that, the particle diameter of described Radix Ginseng powder is: 2mm.
10. the preparation method of the medicine for the treatment of heart failure according to claim 5, is characterized in that, the particle diameter of described Tokay Gecko is: 2mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310609028.0A CN103585215A (en) | 2013-11-26 | 2013-11-26 | Medicine for treating heart failure and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310609028.0A CN103585215A (en) | 2013-11-26 | 2013-11-26 | Medicine for treating heart failure and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103585215A true CN103585215A (en) | 2014-02-19 |
Family
ID=50075669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310609028.0A Pending CN103585215A (en) | 2013-11-26 | 2013-11-26 | Medicine for treating heart failure and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103585215A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107812059A (en) * | 2016-09-14 | 2018-03-20 | 王伟 | A kind of new application of Chinese medicine composition |
| CN110772551A (en) * | 2018-07-30 | 2020-02-11 | 复旦大学 | Compound preparation for treating heart failure |
-
2013
- 2013-11-26 CN CN201310609028.0A patent/CN103585215A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 周莉等: "参蛤散对压力负荷性大鼠心室重构的干预研究", 《2011·中国医师协会中西医结合医师大会论文集》 * |
| 周莉等: "参蛤散对压力负荷性心室重构大鼠射血分数及左心室重量指数的影响", 《四川中医》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107812059A (en) * | 2016-09-14 | 2018-03-20 | 王伟 | A kind of new application of Chinese medicine composition |
| CN107812059B (en) * | 2016-09-14 | 2021-07-02 | 王伟 | Application of traditional Chinese medicine composition |
| CN110772551A (en) * | 2018-07-30 | 2020-02-11 | 复旦大学 | Compound preparation for treating heart failure |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258563A (en) | Anti-cancer medicinal composition and Chinese medicinal composition | |
| CN1305513C (en) | Broad-spectrum cancer-treating Chinese medicine prepn and its prepn process | |
| CN103386078B (en) | A kind of Chinese medicine composition is preparing the application in treating colon cancer drug | |
| CN103405655A (en) | Traditional Chinese medicine composition for reducing blood glucose and preparation method thereof | |
| CN103585215A (en) | Medicine for treating heart failure and preparation method thereof | |
| CN104758404A (en) | Three-snake powder composition for treating autoimmune diseases, and preparation method thereof | |
| CN101091769A (en) | Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method | |
| CN102579999A (en) | Medicine for treating carcinous fever and preparation method thereof | |
| CN101810826B (en) | Chinese medicament for treating liver cancer | |
| CN103392986B (en) | Gerocomia wheat flour and preparation method thereof | |
| CN103341096A (en) | Medicine for treating hyperplasia of mammary glands and preparation method thereof | |
| CN102641448B (en) | Anti-lung-cancer traditional Chinese medicine composite, preparation method of composite, and application of composite in preparation of anti-lung-cancer medicament | |
| CN104524163B (en) | A kind of Chinese medicine composition and preparation method for the treatment of chronic bronchitis and merging pulmonary carcinoma | |
| CN107281386A (en) | Method and the application for the treatment of hypertension drug are prepared with dendrobium candidum and radish seed | |
| CN102008688A (en) | Medicament for treating periodic psychosis | |
| CN103536745B (en) | A kind of Chinese kmedicine bolus for the treatment of cyclomastopathy | |
| CN105287755A (en) | Traditional Chinese medicinal composition for treating sepsis myocardial dysfunction | |
| CN103877411A (en) | Medicinal composition for preventing and treating myocardial fibrosis and application thereof | |
| CN104888149A (en) | Drug for treating cervical cancer and preparation method for drug | |
| CN103933169B (en) | A kind of Chinese medicine composition for fumigation treatment deafness and tinnitus and its preparation method and application | |
| CN108553585A (en) | It is a kind of to treat lipoma and fibromatous Chinese medicine preparation and preparation method thereof | |
| CN102106909B (en) | Fuzheng Zengxiao Anti-cancer Chinese herbal medicine and preparation method thereof | |
| CN100998756A (en) | Traditional Chinese medicine capsule for treating cardiac failure | |
| CN101991645A (en) | Preparation for treating coronary heart disease and preparation method thereof | |
| CN105362423A (en) | Traditional Chinese medicine preparation for treating phlegm-damp stagnation type stomach cancer, method for preparing traditional Chinese medicine preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140219 |